CD19 and precursor B-cell acute lymphoblastic leukemia: Given that CIMLNK derived from either the original matched sibling or haploidentical family donor can be readily available and that TAFA is actively being tested in pediatric B-ALL, the CIMLNK+TAFA combination could serve a viable alternative approach for patients with relapsed CD19+ B-ALL.